United Therapeutics share price today
(NASDAQ: UTHR)

Name: United Therapeutics Share Price Today (NASDAQ: UTHR) - United Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

United Therapeutics share price is $371.89 & ₹32,164.77 as on 24 Jan 2025, 2.30 'hrs' IST

$371.89

▲

0.61

(0.16%)

Market is closed - opens 8 PM, 24 Jan 2025

View live United Therapeutics share price in Dollar and Rupees. Guide to invest in United Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in United Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

United Therapeutics share price movements

Today's Low: $367.02
Today's High: $374.08
$371.89
1.31%
Downside
Day's Volatility :1.89%
Upside
0.59%
52 Weeks Low: $208.62
52 Weeks High: $417.82
$371.89
43.9%
Downside
52 Weeks Volatility :50.07%
Upside
10.99%

United Therapeutics Returns

Period	United Therapeutics Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	6.49%	-5.5%	0.0%
6 Months	9.77%	-4.3%	0.0%
1 Year	69.29%	1.6%	0.0%
3 Years	85.9%	9.8%	-11.0%

United Therapeutics Key Statistics

in dollars & INR

Previous Close	$371.28
Open	$372.55
Today's High	$374.08
Today's Low	$367.02
Market Capitalization	$16.6B
Today's Volume	$317.3K
52 Week High	$417.815
52 Week Low	$208.6249
Revenue TTM	$2.8B
EBITDA	$1.4B
Earnings Per Share (EPS)	$22.78
PE Ratio	16.3
Profit Margin	40.31%
Quarterly Earnings Growth YOY	0.19%
Return On Equity TTM	18.81%

How to invest in United Therapeutics Stock (UTHR) from India?

It is very easy for Indian residents to invest directly in United Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the United Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for United Therapeutics or UTHR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of United Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of United Therapeutics shares which would translate to 0.002 fractional shares of United Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like United Therapeutics, in just a few clicks!

Returns in United Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

United Therapeutics investment value today

Current value as on today

₹1,73,619

Returns

₹73,619

(+73.62%)

Returns from United Therapeutics Stock

₹69,565 (+69.57%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards United Therapeutics

-43%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for United Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -43% less investors are searching United Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in United Therapeutics

BlackRock Inc
11.91%
Vanguard Group Inc
9.88%
Wellington Management Company LLP
7.10%
venBio Select Advisor LLC
6.40%
State Street Corp
5.01%
Renaissance Technologies Corp
4.83%

Analyst Recommendation on United Therapeutics

Buy

81%Buy

13%Hold

4%Sell

Based on 22 Wall street analysts offering stock ratings for United Therapeutics(by analysts ranked 0 to 5 stars)

Based on 22 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on United Therapeutics

What analysts predicted

Upside of 7.02%

Target:

$398.00

Current:

$371.89

Insights on United Therapeutics

Price Movement
In the last 1 year, UTHR stock has moved up by 70.5%
Increasing Revenue
Revenue is up for the last 8 quarters, 491.5M → 748.9M (in $), with an average increase of 5.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 278.1M → 309.1M (in $), with an average increase of 10.0% per quarter
UTHR vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 9.8%

United Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.6B	↓ 5.65%
Net Income	$589.2M	↑ 40.99%
Net Profit Margin	36.2%	↑ 11.98%

	FY19	Y/Y Change
Revenue	$1.4B	↓ 11.0%
Net Income	$-104.5M	↓ 117.74%
Net Profit Margin	-7.21%	↓ 43.41%

	FY20	Y/Y Change
Revenue	$1.5B	↑ 2.38%
Net Income	$514.8M	↓ 592.63%
Net Profit Margin	34.71%	↑ 41.92%

	FY21	Y/Y Change
Revenue	$1.7B	↑ 13.63%
Net Income	$475.8M	↓ 7.58%
Net Profit Margin	28.23%	↓ 6.48%

	FY22	Y/Y Change
Revenue	$1.9B	↑ 14.88%
Net Income	$727.3M	↑ 52.86%
Net Profit Margin	37.56%	↑ 9.33%

	FY23	Y/Y Change
Revenue	$2.3B	↑ 20.2%
Net Income	$984.8M	↑ 35.4%
Net Profit Margin	42.31%	↑ 4.75%

	Q2 FY23	Q/Q Change
Revenue	$596.5M	↑ 17.68%
Net Income	$259.2M	↑ 7.6%
Net Profit Margin	43.45%	↓ 4.07%

	Q3 FY23	Q/Q Change
Revenue	$609.4M	↑ 2.16%
Net Income	$267.6M	↑ 3.24%
Net Profit Margin	43.91%	↑ 0.46%

	Q4 FY23	Q/Q Change
Revenue	$614.7M	↑ 0.87%
Net Income	$217.1M	↓ 18.87%
Net Profit Margin	35.32%	↓ 8.59%

	Q1 FY24	Q/Q Change
Revenue	$677.7M	↑ 10.25%
Net Income	$306.6M	↑ 41.23%
Net Profit Margin	45.24%	↑ 9.92%

	Q2 FY24	Q/Q Change
Revenue	$714.9M	↑ 5.49%
Net Income	$278.1M	↓ 9.3%
Net Profit Margin	38.9%	↓ 6.34%

	Q3 FY24	Q/Q Change
Revenue	$748.9M	↑ 4.76%
Net Income	$309.1M	↑ 11.15%
Net Profit Margin	41.27%	↑ 2.37%

	FY18	Y/Y Change
Profit	$1.4B	↓ 11.76%

	FY19	Y/Y Change
Profit	$1.3B	↓ 6.85%

	FY20	Y/Y Change
Profit	$1.4B	↑ 3.31%

	FY21	Y/Y Change
Profit	$1.6B	↑ 13.66%

	FY22	Y/Y Change
Profit	$1.8B	↑ 14.5%

	FY23	Y/Y Change
Profit	$2.1B	↑ 15.67%

	Q2 FY23	Q/Q Change
Profit	$532.4M	↑ 17.11%

	Q3 FY23	Q/Q Change
Profit	$539.3M	↑ 1.3%

	Q4 FY23	Q/Q Change
Profit	$543.7M	↑ 0.82%

	Q1 FY24	Q/Q Change
Profit	$604.8M	↑ 11.24%

	Q2 FY24	Q/Q Change
Profit	$637.1M	↑ 5.34%

	Q3 FY24	Q/Q Change
Profit	$665.8M	↑ 4.5%

	FY18	Y/Y Change
Operating Cash Flow	$778.4M	↑ 64.15%
Investing Cash Flow	$-820.6M	↓ 1.8%
Financing Cash Flow	$6.3M	↓ 85.45%

	FY19	Y/Y Change
Operating Cash Flow	$-206.6M	↓ 126.54%
Investing Cash Flow	$-335.4M	↓ 59.13%
Financing Cash Flow	$611.2M	↑ 9601.59%

	FY20	Y/Y Change
Operating Cash Flow	$755.7M	↓ 465.78%
Investing Cash Flow	$-738.5M	↑ 120.18%
Financing Cash Flow	$-16.9M	↓ 102.77%

	FY21	Y/Y Change
Operating Cash Flow	$598.2M	↓ 20.84%
Investing Cash Flow	$-486.9M	↓ 34.07%
Financing Cash Flow	$44.8M	↓ 365.09%

	FY22	Y/Y Change
Operating Cash Flow	$802.5M	↑ 34.15%
Investing Cash Flow	$-811.5M	↑ 66.67%
Financing Cash Flow	$75.4M	↑ 68.3%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$106.3M	↓ 71.64%
Investing Cash Flow	$-227.2M	↑ 2.76%
Financing Cash Flow	$24.7M	↓ 49.18%

United Therapeutics Technicals Summary

Sell

Neutral

Buy

United Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

United Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
United Therapeutics Corporation	1.97%	9.77%	69.29%	85.9%	108.8%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
United Therapeutics Corporation	16.3	16.3	1.43	24.67	0.19	0.12	NA	136.74
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
United Therapeutics Corporation	Buy	$16.6B	108.8%	16.3	40.31%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Organization	United Therapeutics
Employees	1168
CEO	Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Industry	Health Technology

Management People of United Therapeutics

Name	Title
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO
Mr. Michael I. Benkowitz	President & COO
Mr. James C. Edgemond	CFO & Treasurer
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary
Mr. Dewey Steadman C.F.A.	Head of Investor Relations
Ms. Holly Hobson	Associate Vice President of Human Resources
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics
Mr. Patrick Poisson	Executive VP of Technical Operations
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation
Mr. Gil Golden	Senior VP & Chief Medical Officer

Important FAQs about investing in United Therapeutics (UTHR) from India :

What is United Therapeutics share price today?

United Therapeutics share price today stands at $371.89, Open: $372.55 ; Previous Close: $371.28 ; High: $374.08 ; Low: $367.02 ; 52 Week High: $417.82 ; 52 Week Low: $208.62. The stock opens at $372.55, after a previous close of $371.28. The stock reached a daily high of $374.08 and a low of $367.02, with a 52-week high of $417.82 and a 52-week low of $208.62.

Can Indians buy United Therapeutics shares?

Yes, Indians can invest in the United Therapeutics (UTHR) from India.

With INDmoney, you can buy United Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy United Therapeutics at zero transaction cost.

How can I buy United Therapeutics shares from India?

It is very easy to buy United Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of United Therapeutics be purchased?

Yes, you can buy fractional shares of United Therapeutics with INDmoney app.

What are the documents required to start investing in United Therapeutics stocks?

To start investing in United Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.